Primary duodenal follicular lymphoma successfully treated with rituximab.
Non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract is the most common extranodal lymphoma, accounting for approximately 40% of all extranodal NHLs. Initial treatment of duodenal lymphoma includes surgery, chemotherapy and radiotherapy, alone or in combination. Here, we present a case of stage I primary duodenal follicular lymphoma (FL) showing a complete response after rituximab therapy. Rituximab alone can be an effective alternative treatment for duodenal FL.
Aguiar-Bujanda
D
D
Servicio de Oncología Médica, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain. dagubuj@gobiernodecanarias.org
Quiñones-Morales
I
I
Camacho-Galán
R
R
Llorca-Martínez
I
I
Rivero-Vera
J C
JC
Bohn-Sarmiento
U
U
Aguiar-Morales
J
J
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004379:Duodenal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab